Volume 10, Issue 1 (2022)
Health Educ Health Promot 2022, 10(1): 201-206 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khodaparast Zavareh M, Abdollah Zadeh Arpanahi M, Gholami Fesharaki M, Sadeghi Ghahrodi M, Mousavi S, Ghazale A, et al . The Risk Factors for Mortality of Adult Inpatients with Covid-19 in Tehran, Iran: A Retrospective Cohort Study. Health Educ Health Promot 2022; 10 (1) :201-206
URL: http://hehp.modares.ac.ir/article-5-57448-en.html
URL: http://hehp.modares.ac.ir/article-5-57448-en.html
M. Khodaparast Zavareh1, M. Abdollah Zadeh Arpanahi2, M. Gholami Fesharaki3, M. Sadeghi Ghahrodi *4, S.V. Mousavi2, A.H. Ghazale4, L. Khedmat5, A. Asadollah6
1- “Department of Echocardiography, School of Medicine” and “Atherosclerosis Research Center”, Baqiyatallah University of Medical Sciences, Tehran, Iran
2- Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
3- Biostatistics Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4- “Department of Echocardiography, School of Medicine” and “Department of Cardiology, School of Medicine”, Baqiyatallah University of Medical Sciences, Tehran, Iran
5- Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
6- Faculty of Medicine, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
2- Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
3- Biostatistics Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4- “Department of Echocardiography, School of Medicine” and “Department of Cardiology, School of Medicine”, Baqiyatallah University of Medical Sciences, Tehran, Iran
5- Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
6- Faculty of Medicine, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
Abstract: (1142 Views)
Aims: Considering the importance of mortality management in the control of COVID-19 disease, this study was performed to investigate the risk factors of mortality of adult inpatients with Covid-19 in Tehran, Iran using a retrospective cohort study.
Material & Methods: This retrospective cohort study was performed among a random sample of confirmed COVID-19 hospitalized patients, in a main general military hospital in Tehran city (Iran). Laboratory data, clinical sign and symptom, treatment and demographic data were collected and compared between survivors and non-survivors patients.
Findings: Among 393 patients who contributed in this study, 37 (9.4%) with 95% confidence interval (6.7% to 12.7%) died during hospitalization. The result of this study also showed that comorbidity like hypertension and CHF, vital sign like dyspnea, RR>24 and Oxygen saturation also laboratory variable like white blood cell, Lymphocyte, C-reactive protein, CR, ESR, Lactate dehydrogenase, Sodium, troponin, Procalcitonin in addition lesion type shown the significant relationship with patients death. The findings of this study showed that the use of drug including Kaltra, Vancomycin, Ribavirin, Meropenem, Levofloxasin, and Methyiprednisolon increased the risk of death but use of drug like Azithromycin, Hydroxychloroquin and Naproxen decrease risk of death in COVID-19 hospitalized patients. More results also showed that ARDS, acute kidney injury and intubation are the most cause of death among patients.
Conclusion: According to the risk factors identified in this study, patients with a higher chance of death can be identified and the necessary treatment measures can be taken to reduce the risk of COVID-19 hospitalized patients.
Material & Methods: This retrospective cohort study was performed among a random sample of confirmed COVID-19 hospitalized patients, in a main general military hospital in Tehran city (Iran). Laboratory data, clinical sign and symptom, treatment and demographic data were collected and compared between survivors and non-survivors patients.
Findings: Among 393 patients who contributed in this study, 37 (9.4%) with 95% confidence interval (6.7% to 12.7%) died during hospitalization. The result of this study also showed that comorbidity like hypertension and CHF, vital sign like dyspnea, RR>24 and Oxygen saturation also laboratory variable like white blood cell, Lymphocyte, C-reactive protein, CR, ESR, Lactate dehydrogenase, Sodium, troponin, Procalcitonin in addition lesion type shown the significant relationship with patients death. The findings of this study showed that the use of drug including Kaltra, Vancomycin, Ribavirin, Meropenem, Levofloxasin, and Methyiprednisolon increased the risk of death but use of drug like Azithromycin, Hydroxychloroquin and Naproxen decrease risk of death in COVID-19 hospitalized patients. More results also showed that ARDS, acute kidney injury and intubation are the most cause of death among patients.
Conclusion: According to the risk factors identified in this study, patients with a higher chance of death can be identified and the necessary treatment measures can be taken to reduce the risk of COVID-19 hospitalized patients.
Article Type: Original Research |
Subject:
Social Health
Received: 2021/11/27 | Accepted: 2022/03/15 | Published: 2022/04/10
Received: 2021/11/27 | Accepted: 2022/03/15 | Published: 2022/04/10
References
1. Molaei A, Fesharaki M G. The geographic distribution of excess mortality rate due to covid-19 in Iranian population: an ecological study. Iranian Red Cres Med J. 2021;23(11). [Link] [DOI:10.21203/rs.3.rs-122870/v1]
2. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PloS One. 2020;15(8):e0238215. [Link] [DOI:10.1371/journal.pone.0238215]
3. Nikpouraghdam M, Jalali Farahani A, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: a single center study. J Clin Virol. 2020;127:104378. [Link] [DOI:10.1016/j.jcv.2020.104378]
4. Lu L, Zhong W, Bian Z, Li Z, Zhang K, Liang B, et al. A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis. J Infect. 2020;81(4):e18-25. [Link] [DOI:10.1016/j.jinf.2020.07.002]
5. Sadeghi Ghahrodi M, Mousavi SV, Dadjou Y, Khedmat L, Abdollah Zadeh Arpanahi M, Jafari R, et al. COVID-19 prognosis in patients with/without a history of ACEI/ARB consumption. Iran Heart J. 2022;23(1):129-39. [Link]
6. Najafi A, Ghanei M, Janbabaei G, Velayati AA, Saadat SH, Jamaati H, et al. Real clinical practice and therapeutic management following COVID-19 crisis in two hospitals in Iran: a statistical and conceptual view. Tanaffos. 2020;19(2):112-21. [Link]
7. Adeli M, Fesharaki M G. Evaluation of COVID-19 treatment outcomes in a military hospital and its comparison with a nonmilitary hospital. J Mil Med. 2021;23(8):675-83. [Persian] [Link]
8. Keeley P, Buchanan D, Carolan C, Pivodic L, Tavabie S, Noble S. Symptom burden and clinical profile of COVID-19 deaths: a rapid systematic review and evidence summary. BMJ Support Palliat Care. 2020;10:381-4. [Link] [DOI:10.1136/bmjspcare-2020-002368]
9. Rastad H, Karim H, Ejtahed HS, Tajbakhsh R, Noorisepehr M, Babaei M, et al. Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. Diabet Metab Syndr. 2020;12:57. [Link] [DOI:10.1186/s13098-020-00565-9]
10. Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh A, et al. Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study. Rom J Intern Med. 2020;58(3):161-7. [Link] [DOI:10.2478/rjim-2020-0013]
11. Homayounieh F, Zhang EW, Babaei R, Karimi Mobin H, Sharifian M, Mohseni I, et al. Clinical and imaging features predict mortality in COVID-19 infection in Iran. PloS One. 2020;15(9):e0239519. [Link] [DOI:10.1371/journal.pone.0239519]
12. Zali A, Gholamzadeh S, Mohammadi G, Azizmohammad Looha M, Akrami F, Zarean E, et al. Baseline characteristics and associated factors of mortality in Covid-19 patients; an analysis of 16000 cases in Tehran, Iran. Arch Acad Emerg Med. 2020;8(1):e70. [Link]
13. Allameh SF, Nemati S, Ghalehtaki R, Mohammadnejad E, Aghili SM, Khajavirad N, et al. Clinical characteristics and outcomes of 905 Covid-19 patients admitted to Imam Khomeini Hospital Complex in the capital city of Tehran, Iran. Arch Iran Med. 2020;23(11):766-75. [Link] [DOI:10.34172/aim.2020.102]
14. Shahriarirad R, Khodamoradi Z, Erfani A, Hosseinpour H, Ranjbar K, Emami Y, et al. Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. BMC Infect Dis. 2020;20: 427. [Link] [DOI:10.1186/s12879-020-05128-x]
15. Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet. 2020;8(5):e639-40. [Link] [DOI:10.1016/S2214-109X(20)30114-5]
16. Sahu P, Galhotra A, Raj U, et al. A study of self-reported health problems of the people living near railway tracks in Raipur city. J Fam Med Primary Care. 2020;9(2):740-4. [Link] [DOI:10.4103/jfmpc.jfmpc_1029_19]
17. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-5. [Link] [DOI:10.1016/S0140-6736(20)30317-2]
18. Ghazale AH, Saloo S, Banadkooki A MD, et al. Evaluation of the effect of combination therapy on treatment of Covid-19: a cohort study. Iran Red Crescent Med J. 2021;23(6). [Link]
19. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;20(4):425-34. [Link] [DOI:10.1016/S1473-3099(20)30086-4]
20. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest ct during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020;295(3):715-21. [Link] [DOI:10.1148/radiol.2020200370]
21. Malekpour Alamdari N, Afaghi S, Rahimi FS, Esmaeili Tarki F, Tavana S, Zali A, et al. Mortality risk factors among hospitalized covid-19 patients in a major referral center in Iran. Tohoku J Exp Med. 2020;252(1):73-84. [Link] [DOI:10.1620/tjem.252.73]
22. Dorjee K, Kim H, Bonomo E, Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PloS One. 2020;15(12):e0243191. [Link] [DOI:10.1371/journal.pone.0243191]
23. Abdoli A. Iran, sanctions, and the COVID-19 crisis. J Med Econ. 2020;30(12):1461-5. [Link] [DOI:10.1080/13696998.2020.1856855]
24. Ali H, Daoud A, Mohamed MM, Abdul Salim S, Yessayan L, Baharani J, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Renal Fail. 2020;42(1):393-7. [Link] [DOI:10.1080/0886022X.2020.1756323]
25. Borges do Nascimento IJ, von Groote TC, O'Mathúna DP, Abdulazeem HM, Henderson C, Jayarajah U, et al. Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: A systematic review and series of meta-analyses. PloS One. 2020;15(9):e0239235. [Link] [DOI:10.1371/journal.pone.0239235]
26. Simadibrata DM, Lubis AM. D-dimer levels on admission and all-cause mortality risk in COVID-19 patients: a meta-analysis. Epidemiol Infect. 2020;148:e202. [Link] [DOI:10.1017/S0950268820002022]
27. Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei Sh, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur J Med Res. 2020;25:30. [Link] [DOI:10.1186/s40001-020-00432-3]
28. Alnor A, Sandberg MB, Gils C, Vinholt PJ. Laboratory tests and outcome for patients with coronavirus disease 2019: a systematic review and meta-analysis. J Appl Lab Med. 2020;5(5):1038-49. [Link] [DOI:10.1093/jalm/jfaa098]
29. Wu X, Liu L, Jiao J, Yang L, Zhu B, Li X. Characterisation of clinical, laboratory and imaging factors related to mild vs. severe covid-19 infection: a systematic review and meta-analysis. Ann Med. 2020;52(7):334-44. [Link] [DOI:10.1080/07853890.2020.1802061]
30. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N En J Med. 2020;382:970-1 [Link] [DOI:10.1056/NEJMc2001468]
31. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-5. [Link] [DOI:10.1073/pnas.2005615117]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |